OpenEvidence’s $15 Billion Valuation Puts Health AI in the Spotlight

OpenEvidence, an AI search engine for doctors, recently raised $250 million from hospital systems and Andreessen Horowitz, according to Business Insider. The round values the Miami-based startup at $15 billion, up from a reported $12 billion valuation in January.

The funding underscores continued investor demand for healthcare-focused AI companies, especially tools built for clinical workflows and physician use.

Business Insider describes OpenEvidence as a “ChatGPT for doctors” and reports that the company has attracted major investors including Nvidia, Thrive Capital, Kleiner Perkins, a16z, and Sequoia Capital. The company has called its AI-powered search engine “the fastest-growing application for physicians in history.”

For readers tracking AI startups, the key signal is clear: specialized AI products with professional users can command premium valuations when they combine adoption, domain expertise, and access to sensitive industry data.

The new round comes as OpenAI, Anthropic, and other AI companies push deeper into healthcare, Business Insider reports. Instead of only supplying models for other companies’ products, major AI firms are increasingly building healthcare tools themselves.

OpenEvidence may be strategically valuable because it already has doctors using its product, experience handling sensitive medical information, and relationships with large technology companies.

Business Insider reports that OpenEvidence could be open to selling itself, though it could not verify whether possible acquirers have shown M&A interest, and the company may prefer to remain independent. The company also has ties across the AI ecosystem: it counts Nvidia as an investor, has an Anthropic partnership, and integrates with Google and Microsoft AI tools.

The broader takeaway is that AI healthcare startups are moving from experimentation to strategic infrastructure, making funding, partnerships, and potential acquisitions worth watching closely.